PGIM Jennison Health Sciences Z
Name
Price
Aum/Mkt Cap
YIELD & DIV
Exp Ratio
Watchlist
Vitals
YTD Return
5.5%
1 yr return
19.5%
3 Yr Avg Return
11.5%
5 Yr Avg Return
15.9%
Net Assets
$2.31 B
Holdings in Top 10
41.1%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 0.85%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 45.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$0
IRA
N/A
Fund Classification
Fund Type
Open End Mutual Fund
Investment Style
Health
Name
Price
Aum/Mkt Cap
YIELD & DIV
Exp Ratio
Watchlist
PHSZX - Profile
Distributions
- YTD Total Return 5.5%
- 3 Yr Annualized Total Return 11.5%
- 5 Yr Annualized Total Return 15.9%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.29%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NamePGIM Jennison Health Sciences Fund
-
Fund Family NamePGIM Funds (Prudential)
-
Inception DateJun 30, 1999
-
Shares OutstandingN/A
-
Share ClassInst
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerDavid Chan
Fund Description
The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.
PHSZX - Performance
Return Ranking - Trailing
| Period | PHSZX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 5.5% | -80.1% | 25.3% | 67.29% |
| 1 Yr | 19.5% | -28.4% | 77.3% | 41.21% |
| 3 Yr | 11.5%* | -0.1% | 33.4% | 59.46% |
| 5 Yr | 15.9%* | 2.1% | 32.2% | 16.08% |
| 10 Yr | 19.6%* | 9.8% | 21.9% | 11.29% |
* Annualized
Return Ranking - Calendar
| Period | PHSZX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2020 | 17.7% | -13.6% | 178.2% | 32.95% |
| 2019 | 15.2% | 3.8% | 63.8% | 80.00% |
| 2018 | -13.5% | -49.7% | 21.5% | 81.02% |
| 2017 | 25.8% | -59.8% | 54.4% | 20.74% |
| 2016 | -17.2% | -36.6% | 11.6% | 64.06% |
Total Return Ranking - Trailing
| Period | PHSZX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 5.5% | -80.1% | 25.3% | 67.29% |
| 1 Yr | 19.5% | -30.4% | 77.3% | 38.74% |
| 3 Yr | 11.5%* | -15.9% | 33.4% | 55.87% |
| 5 Yr | 15.9%* | -7.4% | 32.2% | 13.79% |
| 10 Yr | 19.6%* | 9.8% | 21.9% | 10.45% |
* Annualized
Total Return Ranking - Calendar
| Period | PHSZX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2020 | 17.7% | -13.6% | 178.2% | 32.95% |
| 2019 | 15.2% | 3.8% | 63.8% | 80.00% |
| 2018 | -13.5% | -25.3% | 22.2% | 82.48% |
| 2017 | 25.8% | -10.8% | 54.4% | 22.22% |
| 2016 | -17.2% | -36.6% | 11.6% | 73.44% |
NAV & Total Return History
PHSZX - Holdings
Concentration Analysis
| PHSZX | Category Low | Category High | PHSZX % Rank | |
|---|---|---|---|---|
| Net Assets | 2.31 B | 238 K | 50.5 B | 24.29% |
| Number of Holdings | 87 | 11 | 477 | 41.77% |
| Net Assets in Top 10 | 943 M | 2.18 K | 21.1 B | 17.72% |
| Weighting of Top 10 | 41.05% | 8.6% | 94.7% | 41.77% |
Top 10 Holdings
- UnitedHealth Group Inc 6.92%
- Humana Inc 5.64%
- Eli Lilly and Co 5.27%
- Immunomedics Inc 4.95%
- Danaher Corp 4.56%
- Thermo Fisher Scientific Inc 4.33%
- Natera Inc 3.43%
- Apellis Pharmaceuticals Inc 3.21%
- AbbVie Inc 3.17%
- Becton, Dickinson and Co 3.10%
Asset Allocation
| Weighting | Return Low | Return High | PHSZX % Rank | |
|---|---|---|---|---|
| Stocks | 98.12% | 83.68% | 101.79% | 70.89% |
| Other | 1.40% | -24.25% | 7.97% | 9.70% |
| Cash | 0.46% | -0.82% | 10.99% | 49.79% |
| Preferred Stocks | 0.03% | 0.00% | 6.25% | 8.44% |
| Convertible Bonds | 0.00% | 0.00% | 0.10% | 17.30% |
| Bonds | 0.00% | 0.00% | 15.36% | 20.68% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | PHSZX % Rank | |
|---|---|---|---|---|
| Healthcare | 98.40% | 63.33% | 100.00% | 79.32% |
| Basic Materials | 1.60% | 0.00% | 8.13% | 9.70% |
| Utilities | 0.00% | 0.00% | 1.14% | 17.30% |
| Technology | 0.00% | 0.00% | 19.13% | 23.63% |
| Real Estate | 0.00% | 0.00% | 6.13% | 21.10% |
| Industrials | 0.00% | 0.00% | 7.02% | 22.78% |
| Financial Services | 0.00% | 0.00% | 1.92% | 37.55% |
| Energy | 0.00% | 0.00% | 0.80% | 17.30% |
| Communication Services | 0.00% | 0.00% | 7.81% | 19.41% |
| Consumer Defense | 0.00% | 0.00% | 28.21% | 24.89% |
| Consumer Cyclical | 0.00% | 0.00% | 16.95% | 25.32% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | PHSZX % Rank | |
|---|---|---|---|---|
| US | 85.20% | 57.23% | 100.70% | 58.65% |
| Non US | 12.92% | 0.00% | 42.77% | 42.19% |
PHSZX - Expenses
Operational Fees
| PHSZX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.85% | 0.08% | 2.91% | 38.03% |
| Management Fee | 0.73% | 0.00% | 1.25% | 60.89% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| PHSZX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 0.00% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| PHSZX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| PHSZX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 45.00% | 0.00% | 256.00% | 50.91% |
PHSZX - Distributions
Dividend Yield Analysis
| PHSZX | Category Low | Category High | PHSZX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 2.44% | 28.15% |
Dividend Distribution Analysis
| PHSZX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Monthly | Monthly |
Net Income Ratio Analysis
| PHSZX | Category Low | Category High | PHSZX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.29% | -2.54% | 1.92% | 64.94% |
Capital Gain Distribution Analysis
| PHSZX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually |
PHSZX - Fund Manager Analysis
Managers
David Chan
Start Date
Tenure
Tenure Rank
Jun 30, 1999
22.27
22.3%
David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.
Debra Netschert
Start Date
Tenure
Tenure Rank
Jan 28, 2015
6.68
6.7%
Debra Netschert is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Ms. Netschert joined Jennison Associates in January 2008. Prior to Jennison, Ms. Netschert worked at Magnetar Capital where she was a senior analyst responsible for health care coverage with an emphasis on biotechnology and pharmaceutical industries. Prior to her experience at Magnetar Capital, Ms. Netschert worked at Amaranth Advisors as a biotechnology analyst. From 2002 to 2004, she was vice president and senior analyst for biotechnology at Lazard Capital Markets. Ms. Netschert began her research career as an associate biotechnology analyst at UBS in 2000. She received her BS and MS from Boston University.
Daniel Matviyenko
Start Date
Tenure
Tenure Rank
Dec 15, 2020
0.79
0.8%
Daniel joined Jennison in December 2020 as a Managing Director and co-Portfolio Manager of Health Sciences strategies. Before joining Jennison, he was founder, chief investment officer, and portfolio manager at Malleus Capital. Prior to founding Malleus, Dan was a portfolio manager, managing director, and partner at Tudor Investment. Before joining Tudor, he was a portfolio manager and an executive director at UBS O’Connor. Earlier in his career, Dan held various roles as an equity analyst at a number of firms. Dan holds a BS in finance from the University of Connecticut.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.03 | 24.06 | 6.71 | 1.46 |